This observation is supported by the fact that administration of Tocilizumab, a specific anti-IL-6 monoclonal antibody, could increase the number of peripheral lymphocytes and reduce the pulmonary opacification in severe COVID-19 [44]. Here, IL6 is linked to COVID-19.